Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia
Wioleta M Zelek, Ryan J Bevan, Jacqui M Nimo, Maarten Dewilde, Bart De Strooper, Bryan Paul Morgan · 2025
Read Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia by Wioleta M Zelek, Ryan J Bevan, Jacqui M Nimo, Maarten Dewilde, Bart De Strooper, Bryan Paul Morgan (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713241.txt.
Description
Wioleta Zelek and co-authors ferry a complement-blocking drug into the brain to calm Alzheimer's damage in mice, in a 2025 study. Complement, a blood defense arm, can turn on the brain's own cells when it runs wild. The blood-brain barrier keeps most drugs out, though. The team built fusion proteins that block the final attack complex and ride a shuttle across that wall.
The fusions matched their parent antibody in dish tests and crossed a mock barrier. In dosed mice, the drug showed up in brain tissue. Treated brains held fewer complement scraps than untreated ones. Counts of tiny neuron spines rose, a sign that synapses were spared. The treated mice also scored better on thinking tests after one week. The authors see a real shot at complement drugs for dementia.
Catalog record
| CREATOR | Wioleta M Zelek, Ryan J Bevan, Jacqui M Nimo, Maarten Dewilde, Bart De Strooper, Bryan Paul Morgan |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |